Clinical trials: Rituximab, completed
Hairy Cell Leukemia (HCL)
Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus Rituximab
The study will test the effectiveness (rate of complete remissions, total remission rate and duration of remission) and toxicity of the combined immuno/chemotherapy with subcutaneous cladribine (LITAK®) plus anti-CD20* antibody…
- Trial name
- NCT02157181
- Testing
- 2CdA +/- Rituximab
- Where
- 47 sites in Germany
- Volunteers
- 89 people
- Sponsor
- Jurgen Barth
Immune Thrombocytopenic Purpura
Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia
A comparative study with rituximab (100 mg weekly for 4 weeks and 375mg/m2 for once) shows low dose rituximab may be a useful alternative therapy in patients with ITP.The aim of this study is to compare the efficacy and…
- Trial name
- ITP (NCT01719692)
- Testing
- Rituximab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Waldenstrom's Macroglobulinemia
Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)
In this study, we are trying to find out if the combination of these two drugs is effective in treating Waldenstrom's macroglobulinemia (WM).
- Trial name
- NCT00422799
- Testing
- Bortezomib, Rituximab
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Dana-Farber Cancer Institute
MALT LYMPHOMA
Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma
The aim of the study is to assess the therapeutic activity and safety of the combination of Bendamustine and Rituximab in MALT lymphomas.
- Trial name
- NCT01015248
- Testing
- Rituximab and Bendamustine
- Where
- 19 sites in Spain
- Volunteers
- 60 people
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Lymphoma, Non-Hodgkin
Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab
This was a randomized, double-blind, active-controlled, multiple-dose, clinical similarity study to evaluate the efficacy, pharmacokinetics, pharmacodynamics, safety, tolerability and immunogenicity of ABP 798 compared with…
- Trial name
- JASMINE (NCT02747043)
- Testing
- ABP 798, Rituximab
- Where
- 98 sites in United States, Australia and 18 more
- Volunteers
- 256 people
- Sponsor
- Amgen
Waldenstrom's Macroglobulinemia
Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia
The purpose of this study is to determine if the type of Fc gamma RIIIa receptor that a particular patient's immune cells possess influences how they respond to rituximab and other monoclonal antibodies.
- Trial name
- NCT00142155
- Testing
- Rituximab, monoclonal antibodies
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Dana-Farber Cancer Institute
Diffuse Large B-cell Lymphoma, HIV
Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma
The purpose of this study is to establish the safety of rituximab plus cyclophosphamide, doxorubicin, vincristine,prednisone (R-CHOP) in HIV-infected and HIV-uninfected diffuse large B-cell lymphoma (DLBCL) patients in Malawi.
- Trial name
- NCT02660710
- Testing
- R-CHOP
- Where
- Malawi
- Volunteers
- 39 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Lupus Erythematosus, Systemic
Anti-CD20 in Systemic Lupus Erythematosus
The purpose of this study is to determine the safety and effectiveness of rituximab (anti-CD20) in treating systemic lupus erythematosus (SLE).
- Trial name
- NCT00036491
- Testing
- Rituximab
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Adult Acute Lymphocytic Leukemia
German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
The study evaluates the efficacy and tolerability of a dose-reduced chemotherapy for the treatment of elderly patients with acute lymphoblastic leukemia.
- Trial name
- NCT00198978
- Testing
- Cyclophosphamide, Dexamethasone / Prednisolone, Cytarabine
- Where
- Germany
- Volunteers
- 377 people
- Sponsor
- Goethe University
Lymphoma, Non-Hodgkin, Diffuse Large B-cell Lymphoma
Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis
The purpose of this study is to measure the rate of complete response (CR and UCR) at the end of a course of immuno-chemotherapy: before cerebral radiotherapy for PCL after the course of immuno-chemotherapy for aggressive…
- Trial name
- NCT00553943
- Testing
- Rituximab, Cytarabine
- Where
- 46 sites in Belgium, France
- Volunteers
- 60 people
- Sponsor
- Lymphoma Study Association
Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type
Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma
The purpose of this research study is to evaluate a new investigational drug, TAK-659, given in combination with standard chemotherapy, for the treatment of Diffuse Large B-cell Lymphoma (DLBCL).
- Conditions
- Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT03742258
- Testing
- Cyclophosphamide, Doxorubicin Hydrochloride, Prednisone
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Northwestern University
Chemotherapy, Diffuse Large B-Cell Lymphoma (DLBCL), Nos
Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. Annual incidence increases with age and achieves more than 30 per 100 000 patients 65 years old or over.
- Conditions
- Chemotherapy, Diffuse Large B-Cell Lymphoma (DLBCL), Nos, Elderly
- Trial name
- Relyage (NCT04113226)
- Testing
- Rituximab, Lenalidomide 20 MG, Comprehensive Geriatric Assessment (CGA)
- Where
- France
- Volunteers
- 1 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Lymphoma
Biomarkers in Patients With Diffuse Large B-Cell Lymphoma Treated With Combination Chemotherapy With or Without Rituximab
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT01131208
- Testing
- gene expression analysis, laboratory biomarker analysis
- Volunteers
- 200 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Lymphoma
Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00040950
- Testing
- rituximab, agatolimod sodium
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Primary Immune Thrombocytopenia
Efficacy and Safety of Rituximab Given at Fixed Dose (1000 mg on Days 1 and 15) Compared to the Standard Regimen in Adult's Immune Thrombocytopenia
The aim of this large French multicentric retrospective study was to compare the efficacy and safety of two (the standard and the Rheumatoid arthritis) rituximab regimens in adult's immune thrombocytopenia .
- Trial name
- NCT01727232
- Volunteers
- 107 people
- Sponsor
- Henri Mondor University Hospital
Rheumatoid Arthritis
PK, PD, Safety, and Efficacy of SAIT101 Versus MabThera® Versus Rituxan® in Patients With Rheumatoid Arthritis
A randomised, double blind, parallel group, multicentre study yo compare the pharmacokinetics, pharmacokinetics, safety and efficacy of SAIT101 versus MabThera® versus Rituxan® in patients with rheumatoid arthritis.
- Trial name
- NCT02819726
- Testing
- SAIT101, MabThera, Rituxan
- Where
- 75 sites in United States, Bosnia and Herzegovina and 9 more
- Volunteers
- 294 people
- Sponsor
- Archigen Biotech Limited
Leukemia
Fludarabine and Monoclonal Antibody Therapy in Treating Patients With Untreated B-cell Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to…
- Trial name
- NCT00003248
- Testing
- rituximab, fludarabine phosphate
- Where
- 34 sites in United States
- Volunteers
- 104 people
- Sponsor
- Alliance for Clinical Trials in Oncology
B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to establish the safety of orally administered PCI-32765 in combination with fludarabine/cyclophosphamide/rituximab (FCR) and bendamustine/rituximab (BR) in patients with chronic lymphocytic leukemia…
- Trial name
- NCT01292135
- Testing
- PCI-32765
- Where
- 6 sites in United States
- Volunteers
- 33 people
- Sponsor
- Pharmacyclics LLC.
Autoimmune Diseases
Clinical and Immunological Long-term Follow-up of Patients With Pemphigus Included in the "RITUXIMAB 3" Trial
Pemphigus is an autoimmune disease specific to the skin and mucous membranes characterized by the production of IgG4 isotype autoantibodies (AC) directed mainly against two proteins involved in interkeratinocyte adhesion…
- Trial name
- LTFURITUX3 (NCT03790293)
- Testing
- Rituximab, corticosteroids'therapy
- Where
- 25 sites in France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Rouen
Rheumatoid Arthritis, Interstitial Pneumonia
Rituximab in Rheumatoid Arthritis Lung Disease
This study will examine the course of patients with progressive rheumatoid arthritis associated interstitial lung disease (RA-ILD) treated with rituximab for safety and progression-free survival at 48 weeks.
- Trial name
- NCT00578565
- Testing
- Rituximab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Eric Matteson
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.